Member Info for jdt1990

Any possibly why others with tests have been urged to give up manufacturing capacity?

Section V - tender hasn't been awarded to anyone hence Unnamed (None)

Section V. Award of contract
A contract/lot is awarded: No

V.1) Information on non-award
The contract/lot is not awarded

No tenders or requests to participate were received or all were rejected

https://www.find-tender.service.gov.uk/Notice/002876-2021?origin=SearchResults&p=1#V.%20Award%20of%20contract-0

Agreed EER1 - wonder if AVCT were always the govts top choice but the £912m tender was an opportunity for anyone else with a test to come forward to ensure the process was fair - and nothing of any viable standard was put forward?
This is getting interesting.

This board is riddled with them....
https://www.guerillainvesting.co.uk/2009/12/15/stock-bashers-3/#:~:text=Bashers%20bet%20on%20a%20stock,best%20to%20help%20it%20happen.&text=In%20other%20words%2C%20they%20are,least%20not%20in%20that%20stock.
Lesson 1(I am invested in some dog shares - not a post for weeks)
Bashers never bash bad stocks. You can watch the board for stocks with no potential. You’ll see pretty quickly that those stocks don’t have bashers. Bashers only go after stocks that are going upwards or have excellent potential to go up. Bashers get left behind, so they want to bring the price down.
Lesson 2(Quickdraw)
Bashers bring up old news that you have heard many times. All companies always have a few bits of bad news. The basher will post these bits over and over again. The stupid basher will try to make the old news a bit fresher to try to fool you. Don’t be fooled!
Lesson 3 (Ndn)
Bashers post many times a day. They try to wear you out. They comment on everything, every other post, and can answer every question. To hear them say it, they know it all.
There is no positive comment they won’t bash. They try to control the board with their negativity. If they seem to be working on this one stock full time, that’s because they are! Even more than full-time.

Christ I thought we were over all this nonsense months ago. Can't believe I am actually writing this again but here we go...

Quickdraw you are playing a pointless game.

AS sold a portion of his equity to fund a house purchase - well within his rights to and nothing shady, 35% of his shareholding.

The only thing he did wrong there was tell the market what it was for, which gave plebs like you some ammo.
AS has close to 6m options so his sale was really around 4% of his total equity interest. Those options are linked to commercial milestones, revenue and profit targets. AS is therefore aligned to shareholder interest as those options are the value for him, not the relatively small direct shareholding, which he can only exercise once targets are met.

So for anyone to insinuate there was dodgy dealings going on, he uses the company/shareholders to fund his own pockets or is not aligned with investor interest is utterly deluded!

Amen to that Rottnest - too many armchair critics here.....

If this turns out as we hope/expect - I'm wanting a nice aged whisky in my Irish coffee from MB. Owes me more than just a a latte for having to listen to his carp.

Been announced today as on 22nd Roundhowe
https://www.standard.co.uk/news/uk/boris-johnson-map-lockdown-end-february-22-b919523.html

TU should give us some hard numbers to go along with BAMS sales and other licensing deals though, which I think is where some may get a shock. The commercially sensitive nature of all our agreements means it's really hard to put a value on them until they crystallise into hard cash.
This is from the last TU....I think there maybe a EUREKA moment for many in the upcoming one when £5.5m gets blown out of the water.
"Revenues for the period, which include the initial milestone payment from LG Chem, have grown 100% to £5.5m from £2.76m (12 months ended 31 July 2018) and are ahead of market expectations. Importantly revenues from the Affimer® diagnostics business have grown by 130% as more customer evaluations of the Affimer® platform are underway. The Group's order intake and sales pipeline into 2020 are the strongest to date."

Don’t forget hobione that the BOD hold a good chunk of that 250m shares too!

Sadly a lot are probably distracted by crazy rises in all the Bitcoin plays chasing a few ££ there.
I agree though, it’s crazily undervalued on now being able the mine the south pit alone with gold pour under 2 months.
If any other areas come up with good gold grades this is a different level!

Well done all - that has been a nervy few months! Onwards and upwards!

RTC - They make money on volume and spread, providing liquidity not “buying low selling high”. Basics - would have thought by your name you would know that.

Doesn’t suit the agenda infinis so Ndn probably “missed” those!

"And remember , a year later we have just one research use product. Nothing else."
Case in point - clearly nothing else has happened this year.......

I absolutely agree there PL with people being able to question last years timescales and the CEO's actions. AS has made mistakes, more through naivety in my view but as you say who knows. It happens in small businesses that grow rapidly. It would have been great to have a few non execs on board to guide AS through this.
What irks me though is the ranting/moaning apportioning all blame to AVCT/AS with no consideration for what has actually been achieved in that timeframe and the heavy reliance on third parties.

Crikey yeah. Ndn to employee "So I see you have been instrumental in transforming our business but I would like to focus on the fact that you arrived to work at 09:02 last Tuesday and as such, we haven't been able to solve global hunger and poverty. Must do better"

When you boil it all down. Therapeutics and AVA600 was AVCT's focus prior to COVID. To divert the limited resources AVCT had back then (and still do in all honesty) to building products to fight this strange new virus that nobody had any clue about, would have been a very rash move. Covid could have gone in a month, 2 months and it would have been a waste.
This had to be something worth doing and doing properly. It couldn't be done at the monetary or reputational expense of the wider business. The raise gave a bit of safety net on the monetary front but what went to market still had to be top notch to preserve the Affimer IP, which over that period we have seen has interest outside of COVid and it has materialised into revenue generating licensing deals.
What a lot of people don't see here is AS has actually very astutely run a business through a transitionary/transformational period without jeopardising what AVCT is fundamentally about or the balance sheet.
He's building a business step by step.....not madly chasing every avenue. IMO AS will have known Covid was here to stay and the potential longevity of the testing market long before any of us did. Hence, although frustratingly for many has meant delays, means we could be on the cusp of being integral to producing THE BEST test out there.
Talk about marketing for Affimers.....the exponential positive impact of getting that right is huge.

Investing is not just about making money - that's trading. Investors are more aligned to the fundamentals of a business. Look at who we have on board. They will have done their due diligence and know what potential this business has.
Hence we have 2 camps "My test is late and I haven't made money as quick as I though wah wah wah" and "yes its late but jeez it looks like its going to be the best one out there, which is great for the Affimer brand, should bring us plenty of additional licensing agreements and the revenues/big pharma can fund other avenues which are opening up nicely. Should steadily add value over time"

"On the diagnostic side he and Avacta know how to produce affimers with affinity. That’s it. He was clueless in all other aspects of how to get the diagnostic to market"
Exactly - The Affimers were produced early on, AVCT's bread and butter and were clearly very promising, hence the punchy timelines.
To get a final commercial product requires third parties and plenty of them. When you add into that the govt being a third party and customer, plus ever moving goalposts, it's not difficult to see how those timelines slipped.
I'm just not sure what your point is anymore NDN apart from repeating timelines haven't been met? That's part an parcel of R&D.
You seem to ignore all the other avenues that have been opened up in the interim. AVA600 delivered on time. Licensing deals, extension of agreements with big pharmas, collabs with Bruker/Mologic. AVCT have been busy, whilst sadly at the mercy of others delivering on the LFT side.
It's quite clear these delays were frustrating for AS too - but he's stuck at it and we are now on the cusp....
It's time people just gave credit where it is due in what AVCT has achieved and instead of moaning about the LFT not being "on time" looked at the business they are invested in growing substantially.

And to add to that, what AVCT have actually achieved in this period as a small biotech company with 100 or so employees is nothing short of remarkable. No it hasn't translated into revenue YET but boy is it shaping up nicely for the chance of AVCT being a big time biotech company. Look where it has come from - AVCT don't have infinite man power, R&D grants, govt funding, global presences like your GSK's......the company has had to transform itself in under a year to be in a position to capitalise on a number of different opportunities.
Keep it up AS I say - sterling job!
If you are one of the "success" can only be measured by a 5000000% SP rise and LFT selling in the billions 4 days after Covid was announced you may disagree....there'll be a few of those I am sure.